Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

584.04 -7.00 (-1.18%)
Official Closing Price Updated: 7:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers
European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's (NYSE: NVO) popular therapies... 
Via Benzinga
Weight Loss Drugs - Novo Nordisk A Primary Beneficiary In Obesity Space Currently Controlled By Two Players, Says Analyst
Cantor Fitzgerald has initiated coverage on Europe's most valuable company, Novo Nordisk A/S (NYSE: NVO). 
Via Benzinga
Pfizer Halts Development Of Twice-Daily Weight-Loss Drug; PFE Stock Slides
Pfizer said Friday it would not advance development of a twice-daily oral weight-loss drug because of its side effects. PFE stock fell. 
Via Investor's Business Daily
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
Software earnings were strong, while the Fed is shifting toward rate cuts. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
If You Invested $100 In This Stock 10 Years Ago, You Would Have $1,200 Today
Via Benzinga
Eli Lilly's Options: A Look at What the Big Money is Thinking
Via Benzinga
Pfizer’s Stock Is Down 44% YTD As Woes Continue
Pfizer's shares plunged on Friday after the drugmaker halted the trial of its twice-daily obesity drug. 
Via Talk Markets
1 Underrated Reason to Buy Eli Lilly Stock
Eli Lilly has a well-rounded business that can be a good fit for all types of investors. 
Via The Motley Fool
Novo Nordisk Sues Florida Compounding Pharmacies Over Impurities In Products Claiming To Contain Wegovy Ingredient
Novo Nordisk A/S (NYSE: NVO) has reportedly taken legal action against Florida compounding pharmacies, suing one and refiling a lawsuit against another, as it discovered impurities in their products... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Eli Lilly's Weight-Management Drug Outperformed Ozempic. Is It Time to Buy?
Electronic health records say tirzepatide, the active ingredient in Mounjaro and Zepbound, is better at reducing weight than semaglutide, the active ingredient in Ozempic and Wegovy. 
Via The Motley Fool
Counterfeit Ozempic Raises Alarms - Lebanon Reports Hypoglycemia Cases
Lebanese health officials have reported eleven cases of severe hypoglycemia linked to suspected fake versions of Novo Nordisk A/S's (NYSE: NVO)  
Via Benzinga
Elliott Wave Technical Analysis: Eli Lilly & Co.
Looking for a triangle in wave (b) as we seem to be near the end of the correction. 
Via Talk Markets
$1000 Invested In Eli Lilly 10 Years Ago Would Be Worth This Much Today
Via Benzinga
The Best Stocks to Invest $5,000 in Right Now
Here's how to safeguard your money and grow richer. 
Via The Motley Fool
Ozempic Receives Some Very Bad News: Is It Time to Sell Novo Nordisk Stock?
Real-world data showed some real-world advantages for Ozempic's top rival. 
Via The Motley Fool
Lilly's Weight-Loss Drug Wallops Novo's In Head-To-Head Study; Novo Stock Dives
The study examined health care records for more than 41,000 people. 
Via Investor's Business Daily
Eli Lilly's Blockbuster Mounjaro Shows Larger, Faster Weight Loss Than Novo Nordisk's Ozempic In Real World Study
A recent extensive analysis by Truveta Research has  
Via Benzinga
Biotech And Healthcare Portfolio Playbook For December 2023/24
We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January. 
Via Talk Markets
Novo Nordisk's Flexible Pricing Approach: Push for Broader Access, Innovative Payments
Novo Nordisk A/S (NYSE: NVO) is reportedly discussing with healthcare systems to introduce innovative pricing arrangements for its popular weight  
Via Benzinga
3 Top Stocks That'll Make Smart Investors Rich
Long-term investing is one possible path to riches. 
Via The Motley Fool
Is Pfizer Stock a Buy Ahead of This Highly Anticipated Weight Loss Readout?
An upcoming mid-stage readout may not spark a trend reversal in the big pharma's shares. 
Via The Motley Fool
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
There's no time like the present to buy these stocks. 
Via The Motley Fool
Google Leads Five S&P 500 Stocks Near Buy Points
Four of the stocks tripped up after earnings, but quickly bounced back. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Could Ozempic Harm These 3 Medical Device Stocks?
The drug is on track to cause massive competitive shifts in the healthcare sector. 
Via The Motley Fool
$3,000 Invested in These 3 Top Stocks Could Make You Rich in 10 Years
Plug into a trio of megatrends with these three particular tickers. 
Via The Motley Fool
Will Eli Lilly Be Worth More Than Tesla by 2027?
It's a lot more likely than it sounds. 
Via The Motley Fool
3 Healthcare Stocks to Scoop Up as They Change the Medical Landscape
Consider one of these three leading-edge healthcare stocks from companies focused on significant medical innovations. 
Via InvestorPlace
Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This Healthcare Giant
Could AstraZeneca be an under-rated buy right now? 
Via The Motley Fool
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this  
Via Benzinga
Magnificent 7 Take Center Stage In Hedge Fund Portfolios: Analysts Warn Of Extreme Concentration
Hedge fund portfolios are intensifying their focus on technology stocks, with holdings in mega-cap tech reaching record levels. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.